Skip to main content

Reimbursement Rate Updates for COVID-19 Monoclonal Antibody Administration Procedure Codes M0222 and M0223 Effective February 11, 2022

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to eligible clients. Administrative procedures such as prior authorization, precertification, referrals, and claims/encounter data filing may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the client's specific MCO for details.

Starting March 31, 2022, for dates of service on or after February 11, 2022, reimbursement rates for COVID-19 monoclonal antibody administration procedure codes M0222 and M0223 will be implemented for Texas Medicaid and the Children with Special Health Care Needs (CSHCN) Services Program.

To view the updates, click the following link:

COVID-19 Monoclonal Antibody Administration Procedure Codes M0222 and M0223.

Any affected claims that are identified will be reprocessed. Providers are not required to appeal the claims unless they are denied for additional reasons after the claims reprocessing is completed.

For more information, call the TMHP Contact Center at 800-925-9126 or the TMHP-CSHCN Services Program Contact Center at 800-568-2413.